HOME > Investors > Press Releases
2014-01-06
ViroMed Signs Co-Development Agreement with Reyon Pharmaceuticals to Develop VM202-ALS for Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)
2013-06-18
Completes Patient Enrollment/Administration of VM202-DPN Phase II Clinical Study for the Treatment of Diabetic Peripheral Neuropathy
2017-03-06
2017.02. (IR letter) Business Updates
2015-04-28
US FDA Approves VM202 for Phase III Clinical Study of Diabetic Peripheral Neuropathy (DPN)
2014-11-21
Disclosure of Clinical Trial Entry • Exit (Voluntary Disclosure)
1 2 3 4 5 6 7 8 9 10